HOME > TOP STORIES

TOP STORIES

BUSINESS Flatiron Health Joins Hands with National Cancer Center to Start Up Japan Biz

January 27, 2022
BUSINESS Nippon Shinyaku Snags US Commercial Rights to Capricor’s DMD Cell Therapy

January 26, 2022
REGULATORY PMDA to Place Top Priority on Safety Measures under Proposed Emergency Approval System: Chief Executive

January 25, 2022
BUSINESS Novartis Downsizing Tokyo Head Office to Cut Costs and Support Diverse Work Styles

January 24, 2022
REGULATORY Pfizer’s Comirnaty Bags Japan Approval for Ages 5-11; Actemra OK’ed for COVID-19

January 21, 2022
REGULATORY Pfizer’s Comirnaty Clears Key Panel for Ages 5-11; Actemra Set for COVID-19 Nod

January 21, 2022
REGULATORY Macroeconomic Indexing Lacks Perspectives to Promote Innovation, Improve Care: MHLW Bureau Chief

January 20, 2022
REGULATORY Re-Pricing to Hit 23 Drugs in April; Takecab, GLP-1s, Vyndaqel/Vynmac, and More

January 19, 2022
REGULATORY Takecab Faces 2nd “Huge-Seller” Price Slash, All GLP-1 Injectables to Get Cut Too on Market Expansion

January 18, 2022
COMMENTARY Significance and Challenges around Proposed Emergency Approval Scheme, Eyes on Diet Debate

January 17, 2022
BUSINESS Pfizer Files Oral COVID-19 Pill in Japan

January 14, 2022
REGULATORY Pfizer’s Comirnaty Up for PAFSC Review for Ages 5-11 on Jan. 20; Actemra to Add COVID-19 Use

January 14, 2022
BUSINESS Keytruda, Opdivo Neck and Neck in 2021; 6 Drugs Cross 100 Billion Yen Mark: Encise

January 13, 2022
REGULATORY AMED to Set Up SCARDA in March to Spearhead Vaccine Development: President

January 12, 2022
REGULATORY MHLW Eyes Evaluation Indices and Guidelines to Fuel Rollout of SaMD and Cell & Gene Therapies: Official

January 11, 2022
REGULATORY Rewarding Innovation Was the Primary Goal in 2022 Reform Debate: MHLW Official

January 7, 2022
REGULATORY MHLW to Reshuffle Organization by Summer to Further Support Drug Development; Economic Affairs Division to Be Renamed

January 7, 2022
ORGANIZATION FPMAJ to Go Full Force on Honebuto Debate towards Next Off-Year Price Revision: Chief

January 6, 2022
BUSINESS Shionogi’s COVID-19 Pill Submission Delaying into 2022 as Recruitment Hits Snag

January 6, 2022
BUSINESS Nexium and Feburic Generic Debuts Eyed in 2022, but with Caution to Avoid Shortages

January 5, 2022

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…